Hence, under the assumption of constant PSMA PET tracer affinity, the temporary increase in ΔBPND% observed at mid-treatment, despite declining cellularity, may indicate compensatory upregulation of PSMA in surviving tumour cells. The gene discussed is FOLH1; the disease is neoplasm.